GlassScriptPhysician profile
John Schwab
NPI 1295786655
$121,642.68
in general payments reported to CMS, 2019-2025
13 companies · $2,130 in 2025
The $2,130 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $29K · 2021: $39K · 2022: $7,759 · 2023: $2,430 · 2024: $1,549 · 2025: $2,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,975 · Travel and Lodging: $884 · Consulting Fee: $150 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,975.34 |
| Travel and Lodging | $883.92 |
| Consulting Fee | $150.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $109,706.01 | 2019-2025 | Xywav |
| Harmony Biosciences LLC | $7,049.35 | 2020-2025 | Wakix |
| Inspire Medical Systems, INC. | $3,014.39 | 2021-2025 | Inspire |
| Axsome Therapeutics, INC. | $914.02 | 2022-2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $311.01 | 2023-2025 | Lumryz |
| Eisai INC. | $189.67 | 2020-2022 | |
| Novo Nordisk INC | $139.29 | 2019-2025 | Wegovy |
| Idorsia Pharmaceuticals US INC | $92.20 | 2022-2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $73.05 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $51.49 | 2019-2021 | |
| Apria Healthcare LLC | $44.75 | 2021 | |
| Lilly USA, LLC | $41.75 | 2025 | Zepbound |
| Corium, LLC | $15.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Schwab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.